Key Developments: Astellas Pharma Inc (ALPMY.PK)
13.80USD
20 May 2013
$-0.44 (-3.09%)
$14.24
$13.80
$14.12
$13.79
29,783
114,658
$14.65
$9.48
Latest Key Developments (Source: Significant Developments)
Astellas Pharma Inc Announces Treasury Stock Retirement
Astellas Pharma Inc announced that it will retire 11,000,000 shares (a 2.4% stake) of its treasury stock on May 31, 2013. After the retirement, the total of its shares outstanding will be 456,964,635. Full Article
Astellas Pharma Inc Announces Enzalutamide Recommended for Approval in European Union (EU)
Astellas Pharma Inc announced that it has received a positive opinion from the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP), recommending European Commission (EC) approval for Xtandi (enzalutamide) capsules for the treatment of adult men with metastatic castration-resistant prostate cancer whose disease has progressed on or after docetaxel therapy. Full Article
Astellas Pharma Inc and Ambrx Inc Initiate Collaboration for Discovery and Development of Antibody Drug Conjugates for Oncology
Astellas Pharma Inc entered into a collaboration with Ambrx Inc. ("Ambrx") for the discovery and development of antibody drug conjugates ("ADCs"). ADCs allow for the targeted delivery of drugs to the target tissue. Ambrx creates optimized ADCs using its site-specific conjugation technology along with linkers and payloads. In the preclinical setting, Ambrx ADCs have demonstrated high potency and a wider therapeutic index than ADCs created using conventional non-specific conjugation. Ambrx will receive an upfront payment of USD 15 million from Astellas, as well as up to USD 285 million in potential near and long-term research, development, regulatory and sales-based milestones for an undisclosed number of targets for ADCs in oncology. A portion of these milestones, as well as royalties on any net sales, will be contingent on eventual commercialization of products developed as a result of this partnership. Astellas will receive worldwide rights to develop and commercialize ADCs for oncology. Full Article
Astellas Pharma Inc. Announces Approval in Japan for Treating Functional Dyspepsia with Acofide
ZERIA PHARMACEUTICAL CO LTD and Astellas Pharma Inc. announced today that as of March 25, Zeria has obtained the marketing approval of Acofide Tablets 100mg (nonproprietary name: acotiamide hydrochloride hydrate;) for the treatment of functional dyspepsia (FD) from the Ministry of Health, Labour and Welfare in Japan.Acofide has been co-developed by both companies. Full Article
Astellas Pharma Inc Submits Application for Marketing Approval of Ipragliflozin (ASP1941), SGLT2 Inhibitor for Treatment of Type 2 Diabetes in Japan
Astellas Pharma Inc announced that it has submitted a market authorization application for a SGLT2 inhibitor ipragliflozin (generic name; development code: ASP1941) to the Ministry of Health, Labour and Welfare in Japan seeking an approval for the indication of type 2 diabetes. Full Article
Astellas Pharma Inc to Stop Co-development and Commercialization Alliance on FLT3 Tyrosine Kinase Inhibitor with Ambit Biosciences Corporation
Astellas Pharma Inc announced that it has decided to stop the co-development and commercialization alliance on FLT3 tyrosine kinase inhibitor with Ambit Biosciences Corporation, effective September 3, 2013. The alliance was formed in 2009. Full Article
Astellas Pharma Inc Enters License Agreement with Cubist Pharmaceuticals, Inc. to Develop and Commercialize Injectable Cephalosporin Antibiotic Cephalosporin CXA 201
Astellas Pharma Inc announced the execution of a license agreement with Cubist Pharmaceuticals, Inc., under which Cubist Pharmaceuticals has an exclusive right to develop and commercialize injectable cephalosporin antibiotic cephalosporin CXA 201 worldwide. In return for the exclusive license to develop and commercialize CXA 201 in the Territory, Astellas is entitled to receive an up-front payment of USD 25 million from Cubist Pharmaceuticals. Astellas is also eligible to receive contingent payments upon the achievement of certain development, regulatory and commercial milestones. Full Article
UMN Pharma Inc and Astellas Pharma Inc Announce Positive Result of Phase III Clinical Trial
Astellas Pharma Inc. and UMN Pharma Inc. today announced that the summary results for Phase III clinical trials showed non-inferiority of the recombinant seasonal influenza HA vaccine UMN-0502 (ASP7374) in comparison with the egg-derived vaccine in terms of immunogenicity. No major safety problem was also observed in UMN-0502 (ASP7374) in this study. Full Article
Humana Inc and Astellas Pharma Inc's Astellas Scientific and Medical Affairs Inc Form Research Collaboration to Improve Health Care Delivery for Seniors
Humana Inc and Astellas Scientific and Medical Affairs Inc., a U.S. subsidiary of Tokyo-based Astellas Pharma Inc announced a multi-year research collaboration to explore new ideas and ways to improve the health and well-being of patients and members. The two companies will bring together researchers and health care experts from both companies to study key issues and develop ways to reduce inefficiencies in the management of oncology, urology and immunology conditions. Full Article
FDA Accepts Supplemental New Drug Application for Tarceva from Astellas Pharma Inc
Astellas Pharma Inc announced that fda accepts supplemental new drug application for tarceva from astellas pharma inc Full Article
EU body backs new Roche, Astellas, Sanofi, Vivus drugs
LONDON - European regulators have recommended approval of two new cancer drugs, called Erivedge and Xtandi, from Roche and Astellas, underscoring a recent pick-up in novel treatments for the disease.
Earnings vs. 
Estimates
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
